Alembic Pharmaceuticals Limited — Board Meeting, 05-08-2025: Outcome of Board Meeting

Alembic Pharmaceuticals has announced a board meeting where it approved the consolidated financial results for the quarter ended June 30, 2025. The company delivered a solid performance with Revenue from Operations climbing to Rs 1,710.72 Cr, a noticeable increase from Rs 1,561.73 Cr in the same quarter last year. Profit for the period after non-controlling interests also saw healthy growth, reaching Rs 154.38 Cr compared to Rs 134.71 Cr previously. This positive start for the financial year reflects strong operational delivery, signaling momentum for retail investors to watch.